The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier
A 42-year-old female who was an asymptomatic carrier of hepatitis B virus (HBV) was diagnosed with antineutrophil cytoplasm antibody- (ANCA-) associated vasculitis and was induced to remission with 30 mg/day prednisolone nine years ago. Four years ago, she suffered recurrence of ANCA-associated vasc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/929318 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553289561931776 |
|---|---|
| author | Jun Muratsu Atsuyuki Morishima Masayoshi Kukida Anzu Tanaka Shigeki Fujita Katsuhiko Sakaguchi |
| author_facet | Jun Muratsu Atsuyuki Morishima Masayoshi Kukida Anzu Tanaka Shigeki Fujita Katsuhiko Sakaguchi |
| author_sort | Jun Muratsu |
| collection | DOAJ |
| description | A 42-year-old female who was an asymptomatic carrier of hepatitis B virus (HBV) was diagnosed with antineutrophil cytoplasm antibody- (ANCA-) associated vasculitis and was induced to remission with 30 mg/day prednisolone nine years ago. Four years ago, she suffered recurrence of ANCA-associated vasculitis and with 30 mg/day prednisolone was induced to remission. This time, laboratory data showed 3-fold increase in myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) levels. Administration of 30 mg/day prednisolone was started. Three days later, she was admitted to our hospital suffering from fatigue. After admission, urinalysis showed glomerular hematuria. Despite administration of 30 mg/day prednisolone, MPO-ANCA titer had been of high level, ranging from 42 to 83 EU for 2.5 months. Furthermore, the adverse effects of steroid were seen. We decided the tapering of prednisolone (25 mg/day) and the start of mizoribine (4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate) administration. After mizoribine treatment, MPO-ANCA titer was decreased without any mizoribine-related adverse effects. Six months later, MPO-ANCA titer was decreased to normal levels and she was induced to clinical remission without reactivation of HBV. We describe the effectiveness of mizoribine for the ANCA-associated vasculitis complicated with HBV-carrier. |
| format | Article |
| id | doaj-art-bebab2bd7301427098eb3dcfe49cd196 |
| institution | Kabale University |
| issn | 2090-6609 2090-6617 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Immunology |
| spelling | doaj-art-bebab2bd7301427098eb3dcfe49cd1962025-02-03T05:54:30ZengWileyCase Reports in Immunology2090-66092090-66172012-01-01201210.1155/2012/929318929318The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus CarrierJun Muratsu0Atsuyuki Morishima1Masayoshi Kukida2Anzu Tanaka3Shigeki Fujita4Katsuhiko Sakaguchi5Department of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanDepartment of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanDepartment of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanDepartment of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanDepartment of Pathology, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanDepartment of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Kitaku Nakanoshima, Osaka 530-0005, JapanA 42-year-old female who was an asymptomatic carrier of hepatitis B virus (HBV) was diagnosed with antineutrophil cytoplasm antibody- (ANCA-) associated vasculitis and was induced to remission with 30 mg/day prednisolone nine years ago. Four years ago, she suffered recurrence of ANCA-associated vasculitis and with 30 mg/day prednisolone was induced to remission. This time, laboratory data showed 3-fold increase in myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) levels. Administration of 30 mg/day prednisolone was started. Three days later, she was admitted to our hospital suffering from fatigue. After admission, urinalysis showed glomerular hematuria. Despite administration of 30 mg/day prednisolone, MPO-ANCA titer had been of high level, ranging from 42 to 83 EU for 2.5 months. Furthermore, the adverse effects of steroid were seen. We decided the tapering of prednisolone (25 mg/day) and the start of mizoribine (4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate) administration. After mizoribine treatment, MPO-ANCA titer was decreased without any mizoribine-related adverse effects. Six months later, MPO-ANCA titer was decreased to normal levels and she was induced to clinical remission without reactivation of HBV. We describe the effectiveness of mizoribine for the ANCA-associated vasculitis complicated with HBV-carrier.http://dx.doi.org/10.1155/2012/929318 |
| spellingShingle | Jun Muratsu Atsuyuki Morishima Masayoshi Kukida Anzu Tanaka Shigeki Fujita Katsuhiko Sakaguchi The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier Case Reports in Immunology |
| title | The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier |
| title_full | The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier |
| title_fullStr | The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier |
| title_full_unstemmed | The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier |
| title_short | The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier |
| title_sort | efficacy of mizoribine inosine monophosphate dehydrogenase inhibitor for anca associated vasculitis with hepatitis b virus carrier |
| url | http://dx.doi.org/10.1155/2012/929318 |
| work_keys_str_mv | AT junmuratsu theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT atsuyukimorishima theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT masayoshikukida theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT anzutanaka theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT shigekifujita theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT katsuhikosakaguchi theefficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT junmuratsu efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT atsuyukimorishima efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT masayoshikukida efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT anzutanaka efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT shigekifujita efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier AT katsuhikosakaguchi efficacyofmizoribineinosinemonophosphatedehydrogenaseinhibitorforancaassociatedvasculitiswithhepatitisbviruscarrier |